Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?

FDA's finalized guidance on off-label reprints contains small modifications that appear to satisfy free speech critics of the draft version. But it does not offer sufficient change to mollify congressional critics who believe the document is too permissive